# Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT00425360** · PHASE3 · COMPLETED · sponsor: **Royal Liverpool University Hospital** · enrollment: 1110 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** telomerase peptide vaccine GV1001
- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00425360
- **Lead sponsor:** Royal Liverpool University Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2013-03
- **Target enrollment:** 1110 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425360, "Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00425360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*